76 related articles for article (PubMed ID: 35679137)
1. A Bayesian group sequential design for randomized biosimilar clinical trials with adaptive information borrowing from historical data.
Zhang W; Pan Z; Yuan Y
J Biopharm Stat; 2022 May; 32(3):359-372. PubMed ID: 35679137
[TBL] [Abstract][Full Text] [Related]
2. Bayesian borrowing from historical control data in a vaccine efficacy trial.
Peng L; Jin J; Chambonneau L; Zhao X; Zhang J
Pharm Stat; 2023; 22(5):815-835. PubMed ID: 37226586
[TBL] [Abstract][Full Text] [Related]
3. A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling.
Wei W; Blaha O; Esserman D; Zelterman D; Kane M; Liu R; Lin J
Stat Med; 2024 May; 43(12):2439-2451. PubMed ID: 38594809
[TBL] [Abstract][Full Text] [Related]
4. Simulating and reporting frequentist operating characteristics of clinical trials that borrow external information: Towards a fair comparison in case of one-arm and hybrid control two-arm trials.
Kopp-Schneider A; Wiesenfarth M; Held L; Calderazzo S
Pharm Stat; 2024; 23(1):4-19. PubMed ID: 37632266
[TBL] [Abstract][Full Text] [Related]
5. A novel equivalence probability weighted power prior for using historical control data in an adaptive clinical trial design: A comparison to standard methods.
Bennett M; White S; Best N; Mander A
Pharm Stat; 2021 May; 20(3):462-484. PubMed ID: 33474798
[TBL] [Abstract][Full Text] [Related]
6. Alone, together: On the benefits of Bayesian borrowing in a meta-analytic setting.
Harari O; Soltanifar M; Verhoek A; Heeg B
Pharm Stat; 2023; 22(5):903-920. PubMed ID: 37321565
[TBL] [Abstract][Full Text] [Related]
7. A scaled kernel density estimation prior for dynamic borrowing of historical information with application to clinical trial design.
Warren JL; Wang Q; Ciarleglio MM
Stat Med; 2024 Apr; 43(8):1615-1626. PubMed ID: 38345148
[TBL] [Abstract][Full Text] [Related]
8. Bayesian single-to-double arm transition design using both short-term and long-term endpoints.
Xu T; Shi H; Lin R
Pharm Stat; 2023; 22(4):588-604. PubMed ID: 36755420
[TBL] [Abstract][Full Text] [Related]
9. A dynamic power prior approach to non-inferiority trials for normal means.
Mariani F; De Santis F; Gubbiotti S
Pharm Stat; 2024; 23(2):242-256. PubMed ID: 37964403
[TBL] [Abstract][Full Text] [Related]
10. Bayesian order constrained adaptive design for phase II clinical trials evaluating subgroup-specific treatment effect.
Shan M; Guo B; Liu H; Li Q; Zang Y
Stat Methods Med Res; 2023 May; 32(5):885-894. PubMed ID: 36919375
[TBL] [Abstract][Full Text] [Related]
11. Covariate adjustment in Bayesian adaptive randomized controlled trials.
Willard J; Golchi S; Moodie EE
Stat Methods Med Res; 2024 Mar; 33(3):480-497. PubMed ID: 38327082
[TBL] [Abstract][Full Text] [Related]
12. Bayesian sample size determination using commensurate priors to leverage preexperimental data.
Zheng H; Jaki T; Wason JMS
Biometrics; 2023 Jun; 79(2):669-683. PubMed ID: 35253201
[TBL] [Abstract][Full Text] [Related]
13. Evaluating hybrid controls methodology in early-phase oncology trials: A simulation study based on the MORPHEUS-UC trial.
Wang G; Poulin-Costello M; Pang H; Zhu J; Helms HJ; Reyes-Rivera I; Platt RW; Pang M; Koukounari A
Pharm Stat; 2024; 23(1):31-45. PubMed ID: 37743566
[TBL] [Abstract][Full Text] [Related]
14. A comparison of Bayesian information borrowing methods in basket trials and a novel proposal of modified exchangeability-nonexchangeability method.
Daniells L; Mozgunov P; Bedding A; Jaki T
Stat Med; 2023 Oct; 42(24):4392-4417. PubMed ID: 37614070
[TBL] [Abstract][Full Text] [Related]
15. Covariate adjusted meta-analytic predictive (CA-MAP) prior for historical borrowing using patient-level data.
Hupf B; Yang Y; Gryder R; Bunn V; Lin J
J Biopharm Stat; 2024 Apr; ():1-9. PubMed ID: 38562017
[TBL] [Abstract][Full Text] [Related]
16. A framework for testing non-inferiority in a three-arm, sequential, multiple assignment randomized trial.
Paul E; Chakraborty B; Sikorskii A; Ghosh S
Stat Methods Med Res; 2024 Apr; 33(4):611-633. PubMed ID: 38400576
[TBL] [Abstract][Full Text] [Related]
17. A conservative approach to leveraging external evidence for effective clinical trial design.
Rigat F
Pharm Stat; 2024; 23(1):81-90. PubMed ID: 37751940
[TBL] [Abstract][Full Text] [Related]
18. A Bayesian adaptive design with biomarkers for targeted therapies.
Eickhoff JC; Kim K; Beach J; Kolesar JM; Gee JR
Clin Trials; 2010 Oct; 7(5):546-56. PubMed ID: 20571131
[TBL] [Abstract][Full Text] [Related]
19. Adaptively leveraging external data with robust meta-analytical-predictive prior using empirical Bayes.
Zhang H; Shen Y; Li J; Ye H; Chiang AY
Pharm Stat; 2023; 22(5):846-860. PubMed ID: 37220997
[TBL] [Abstract][Full Text] [Related]
20. Bayesian adaptive phase II screening design for combination trials.
Cai C; Yuan Y; Johnson VE
Clin Trials; 2013; 10(3):353-62. PubMed ID: 23359875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
